D. Abe, M. Oba, Y. Murakami, Shinji Hisatake, T. Ikeda
Objective ：The number of heart failure（HF）patients is increasing in Japan as its population continues to age, but little is known about current medication strategies. We investigated the relationship between medication changes during hospitalization and the readmission rate among older Japanese patients with new-onset HF. Design ：Retrospective cohort study. Methods ：We analyzed medical record data from Toho University Medical Center Omori Hospital between March 2004 and April 2018. Initial admissions for new-onset HF in patients aged B 75 years were examined ／ （n＝329). The class Ⅰ recommended medications stipulated in the JCS 2017／JHFS 2017 guidelines were used as the target medications for this study. Patients with dose titrations or additions of the target medications during hospitalization（dose titrations or additions group）were compared with patients without these changes（the other group). The primary outcome was readmission due to HF within one year of discharge. A hazard ratio, adjusted for potential confounders, was estimated using a Cox proportional hazards model. Results ：There were 231 patients in dose titrations or additions group and 98 patients in the other group. The one-year readmission rate was 26.5％ in dose titrations or additions group and 31.8％ in the other group. The adjusted hazard ratio of medication changes for readmission was 0.82（95％ confidence interval, 0.51-1.33, P＝0.415), but was not statistically significant. Conclusion ：The older HF patients in dose titrations or additions group showed a reduced risk of readmission, but lacked significance due to low statistical power.
{"title":"Medication Changes During Hospitalization and Readmission Among Older Patients with Heart Failure in Japan","authors":"D. Abe, M. Oba, Y. Murakami, Shinji Hisatake, T. Ikeda","doi":"10.3820/jjpe.26.e1","DOIUrl":"https://doi.org/10.3820/jjpe.26.e1","url":null,"abstract":"Objective ：The number of heart failure（HF）patients is increasing in Japan as its population continues to age, but little is known about current medication strategies. We investigated the relationship between medication changes during hospitalization and the readmission rate among older Japanese patients with new-onset HF. Design ：Retrospective cohort study. Methods ：We analyzed medical record data from Toho University Medical Center Omori Hospital between March 2004 and April 2018. Initial admissions for new-onset HF in patients aged B 75 years were examined ／ （n＝329). The class Ⅰ recommended medications stipulated in the JCS 2017／JHFS 2017 guidelines were used as the target medications for this study. Patients with dose titrations or additions of the target medications during hospitalization（dose titrations or additions group）were compared with patients without these changes（the other group). The primary outcome was readmission due to HF within one year of discharge. A hazard ratio, adjusted for potential confounders, was estimated using a Cox proportional hazards model. Results ：There were 231 patients in dose titrations or additions group and 98 patients in the other group. The one-year readmission rate was 26.5％ in dose titrations or additions group and 31.8％ in the other group. The adjusted hazard ratio of medication changes for readmission was 0.82（95％ confidence interval, 0.51-1.33, P＝0.415), but was not statistically significant. Conclusion ：The older HF patients in dose titrations or additions group showed a reduced risk of readmission, but lacked significance due to low statistical power.","PeriodicalId":14576,"journal":{"name":"Japanese Journal of Pharmacoepidemiology\\/yakuzai Ekigaku","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83065959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"2．Response to COVID-19 from a Social Welfare Policy Perspective","authors":"I. Wada","doi":"10.3820/JJPE.26.63","DOIUrl":"https://doi.org/10.3820/JJPE.26.63","url":null,"abstract":"","PeriodicalId":14576,"journal":{"name":"Japanese Journal of Pharmacoepidemiology\\/yakuzai Ekigaku","volume":"253 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77141763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"3．Value Assessment of Vaccines and Drugs： Learnings from COVID-19 Pandemic","authors":"Y. Aitoku","doi":"10.3820/JJPE.26.71","DOIUrl":"https://doi.org/10.3820/JJPE.26.71","url":null,"abstract":"","PeriodicalId":14576,"journal":{"name":"Japanese Journal of Pharmacoepidemiology\\/yakuzai Ekigaku","volume":"238 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83474080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"1．COVID-19 and HTA","authors":"A. Igarashi","doi":"10.3820/JJPE.26.56","DOIUrl":"https://doi.org/10.3820/JJPE.26.56","url":null,"abstract":"","PeriodicalId":14576,"journal":{"name":"Japanese Journal of Pharmacoepidemiology\\/yakuzai Ekigaku","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75225634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Probability Weighting Estimator（IPW）and Augmented Inverse Probability Weighting Estimator（AIPW） analyses. Results ：The Odds Ratios（OR）estimated by each method using the time axis of the elapsed time, the prescription number, and the administration time were 1.48（95％CI 0.71-3.11), 1.60（95％CI 0.72-3.55), and 1.04（95％CI 0.58-1.86), respectively. We performed PS weighting, of each Average Treatment Effect obtained from IPW, and the AIPW were estimated to be 0.31％（95％CI −0.91-1.53）and 0.29％（95％CI −0.91-1.49), respectively, and the average treatment effect on the treated was estimated to be 0.10％ （95％CI −1.11-1.32). We support the findings of a previous study which showed that the combination of biologicals was not statistically associated with increased infection risk. Conclusion ：This study suggests that estimators from different perspectives might be obtained by using some epidemiological methods. Therefore, our results could contribute to the establishment of an improved methodology.
{"title":"Validation of Epidemiological Methods for Studying the Infection Risk in Rheumatoid Arthritis with Methotrexate Combined Biologicals using Propensity Scores","authors":"Takuma Koinuma, M. Akazawa","doi":"10.3820/jjpe.26.e3","DOIUrl":"https://doi.org/10.3820/jjpe.26.e3","url":null,"abstract":"Probability Weighting Estimator（IPW）and Augmented Inverse Probability Weighting Estimator（AIPW） analyses. Results ：The Odds Ratios（OR）estimated by each method using the time axis of the elapsed time, the prescription number, and the administration time were 1.48（95％CI 0.71-3.11), 1.60（95％CI 0.72-3.55), and 1.04（95％CI 0.58-1.86), respectively. We performed PS weighting, of each Average Treatment Effect obtained from IPW, and the AIPW were estimated to be 0.31％（95％CI −0.91-1.53）and 0.29％（95％CI −0.91-1.49), respectively, and the average treatment effect on the treated was estimated to be 0.10％ （95％CI −1.11-1.32). We support the findings of a previous study which showed that the combination of biologicals was not statistically associated with increased infection risk. Conclusion ：This study suggests that estimators from different perspectives might be obtained by using some epidemiological methods. Therefore, our results could contribute to the establishment of an improved methodology.","PeriodicalId":14576,"journal":{"name":"Japanese Journal of Pharmacoepidemiology\\/yakuzai Ekigaku","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83195250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：